This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...